Bellerophon Therapeutics (BLPH) Competitors $0.06 +0.02 (+44.74%) (As of 01:57 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSustainabilityTrends BLPH vs. NOVN, PHIO, SBFM, SPRC, PTPI, DRMA, ATNF, NTBL, GRTX, and CMNDShould you be buying Bellerophon Therapeutics stock or one of its competitors? The main competitors of Bellerophon Therapeutics include Novan (NOVN), Phio Pharmaceuticals (PHIO), Sunshine Biopharma (SBFM), SciSparc (SPRC), Petros Pharmaceuticals (PTPI), Dermata Therapeutics (DRMA), 180 Life Sciences (ATNF), Notable Labs (NTBL), Galera Therapeutics (GRTX), and Clearmind Medicine (CMND). These companies are all part of the "pharmaceutical preparations" industry. Bellerophon Therapeutics vs. Novan Phio Pharmaceuticals Sunshine Biopharma SciSparc Petros Pharmaceuticals Dermata Therapeutics 180 Life Sciences Notable Labs Galera Therapeutics Clearmind Medicine Novan (NASDAQ:NOVN) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations. Which has more risk and volatility, NOVN or BLPH? Novan has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Bellerophon Therapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Does the media favor NOVN or BLPH? In the previous week, Bellerophon Therapeutics had 1 more articles in the media than Novan. MarketBeat recorded 1 mentions for Bellerophon Therapeutics and 0 mentions for Novan. Novan's average media sentiment score of 0.00 equaled Bellerophon Therapeutics'average media sentiment score. Company Overall Sentiment Novan Neutral Bellerophon Therapeutics Neutral Do institutionals & insiders have more ownership in NOVN or BLPH? 14.5% of Novan shares are owned by institutional investors. Comparatively, 10.6% of Bellerophon Therapeutics shares are owned by institutional investors. 1.3% of Novan shares are owned by company insiders. Comparatively, 5.2% of Bellerophon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has stronger valuation & earnings, NOVN or BLPH? Bellerophon Therapeutics has lower revenue, but higher earnings than Novan. Bellerophon Therapeutics is trading at a lower price-to-earnings ratio than Novan, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovan$24.71M0.00-$31.31M-$1.32N/ABellerophon TherapeuticsN/AN/A-$19.83M-$0.84-0.07 Is NOVN or BLPH more profitable? Bellerophon Therapeutics has a net margin of 0.00% compared to Novan's net margin of -128.61%. Bellerophon Therapeutics' return on equity of 0.00% beat Novan's return on equity.Company Net Margins Return on Equity Return on Assets Novan-128.61% -700.28% -39.58% Bellerophon Therapeutics N/A N/A N/A Does the MarketBeat Community prefer NOVN or BLPH? Bellerophon Therapeutics received 80 more outperform votes than Novan when rated by MarketBeat users. Likewise, 57.79% of users gave Bellerophon Therapeutics an outperform vote while only 53.11% of users gave Novan an outperform vote. CompanyUnderperformOutperformNovanOutperform Votes23953.11% Underperform Votes21146.89% Bellerophon TherapeuticsOutperform Votes31957.79% Underperform Votes23342.21% SummaryBellerophon Therapeutics beats Novan on 11 of the 13 factors compared between the two stocks. Ad DTII've got news for you… Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekwatch this FREE briefing with me and expert trader Graham Lindman Get Bellerophon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLPH vs. The Competition Export to ExcelMetricBellerophon TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$465,000.00$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E Ratio-0.054.9791.2813.60Price / SalesN/A371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book0.1410.306.906.33Net Income-$19.83M$153.61M$118.83M$225.93M7 Day PerformanceN/A-1.73%-1.92%-0.96%1 Month PerformanceN/A-7.26%-3.75%1.06%1 Year PerformanceN/A31.10%31.37%26.59% Bellerophon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLPHBellerophon Therapeutics0.4751 of 5 stars$0.06+44.7%N/A+9.2%$673,000.00N/A-0.0720NOVNNovanN/AN/AN/AN/A$2.64M$24.71M-0.0790Gap UpHigh Trading VolumePHIOPhio Pharmaceuticals1.6136 of 5 stars$2.51+5.5%$36.00+1,334.3%-73.6%$2.66MN/A-0.228SBFMSunshine Biopharma0.084 of 5 stars$2.13-2.3%N/A-91.9%$2.60M$24.09M0.003SPRCSciSparc0.0985 of 5 stars$0.24+2.6%N/A-96.2%$2.53M$2.88M0.004PTPIPetros Pharmaceuticals2.9627 of 5 stars$0.24-1.1%$4.00+1,536.0%-80.9%$2.45M$5.82M0.0020Gap UpDRMADermata Therapeutics2.2798 of 5 stars$1.19+2.6%$6.00+404.2%-90.7%$2.43MN/A-0.078Positive NewsATNF180 Life Sciences0.2955 of 5 stars$2.31-1.3%N/A-66.6%$2.38MN/A0.007NTBLNotable LabsN/AN/A$7.00+∞-92.7%$2.24M$313,000.000.0040Gap DownHigh Trading VolumeGRTXGalera TherapeuticsN/A$0.04flatN/A-70.0%$2.23MN/A0.0030Gap UpCMNDClearmind Medicine0.1869 of 5 stars$1.31-3.7%N/A-61.9%$2.21MN/A0.00N/ANews Coverage Related Companies and Tools Related Companies Novan Alternatives Phio Pharmaceuticals Alternatives Sunshine Biopharma Alternatives SciSparc Alternatives Petros Pharmaceuticals Alternatives Dermata Therapeutics Alternatives 180 Life Sciences Alternatives Notable Labs Alternatives Galera Therapeutics Alternatives Clearmind Medicine Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BLPH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellerophon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellerophon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
